Advertisement
Research Article Free access | 10.1172/JCI114797
Department of Medicine, University Hospital of Zürich, Switzerland.
Find articles by Zapf, J. in: PubMed | Google Scholar
Department of Medicine, University Hospital of Zürich, Switzerland.
Find articles by Schmid, C. in: PubMed | Google Scholar
Department of Medicine, University Hospital of Zürich, Switzerland.
Find articles by Guler, H. in: PubMed | Google Scholar
Department of Medicine, University Hospital of Zürich, Switzerland.
Find articles by Waldvogel, M. in: PubMed | Google Scholar
Department of Medicine, University Hospital of Zürich, Switzerland.
Find articles by Hauri, C. in: PubMed | Google Scholar
Department of Medicine, University Hospital of Zürich, Switzerland.
Find articles by Futo, E. in: PubMed | Google Scholar
Department of Medicine, University Hospital of Zürich, Switzerland.
Find articles by Hossenlopp, P. in: PubMed | Google Scholar
Department of Medicine, University Hospital of Zürich, Switzerland.
Find articles by Binoux, M. in: PubMed | Google Scholar
Department of Medicine, University Hospital of Zürich, Switzerland.
Find articles by Froesch, E. in: PubMed | Google Scholar
Published September 1, 1990 - More info
Insulin-like growth factors (IGFs) in blood form two complexes with specific binding proteins (BPs): a large, growth hormone (GH)-dependent complex with restricted capillary permeability, and a smaller complex, inversely related to GH, with high turnover of its IGF pool and free capillary permeability. The distribution of BPs and of IGFs I and II between these complexes was studied in sera from healthy adults treated with IGF I or/and GH and from patients with extrapancreatic tumor hypoglycemia. Like GH, IGF I administration raises IGF I and two glycosylation variants of IGFBP-3 in the large complex, but unlike GH drastically reduces IGF II. During IGF I infusion, IGFBP-3 appears in the small complex whose IGFBP-2 and IGF I increase three- to fivefold and fivefold, respectively. GH treatment, associated with elevated insulin levels, suppresses IGFBP-2 and inhibits its increase owing to infused IGF I. The small complex of tumor sera contains increased amounts of IGFBP-2 and -3, and two- to threefold elevated IGF II. Conclusions: low GH and/or insulin during IGF I infusion and in extrapancreatic tumor hypoglycemia enhance expression of IGFBP-2 and favor partition of IGFBP-3 into the small complex. Free capillary passage and high turnover of its increased IGF I or II pools may contribute to compensate for suppressed insulin secretion during IGF I infusion or to development of tumor hypoglycemia.
Images.